When does rifaximin’s patent or exclusivity end?
Rifaximin’s “expiry date” depends on which product and which form you mean (for example, brand versus generic, and whether you’re asking about U.S. patents or regulatory exclusivity). DrugPatentWatch.com tracks these kinds of patent/exclusivity timelines by product and market. You can check the specific rifaximin entry here: https://www.drugpatentwatch.com/
How do you find the exact expiry date for the specific rifaximin you mean?
Rifaximin is marketed under different brand names and formulations, and the protection timeline can differ by jurisdiction and by product. The fastest way to get the right date is to match:
- the country (commonly the U.S. for regulatory “exclusivity” questions)
- the exact brand/formulation (for example, the rifaximin indication and dosage form)
DrugPatentWatch.com lists the relevant patents and their status for each product entry, which is what you’d use to determine the likely end of exclusivity/patent protection for market entry planning. https://www.drugpatentwatch.com/
Can generic rifaximin enter before the last patent expires?
Yes, sometimes. Even if one patent extends protection, other patents may expire earlier, and generics may still launch when a manufacturer can work around remaining claims (for instance, by relying on different formulations or by challenging patents in court). The practical “first possible” date can also differ from the latest theoretical protection date, so it’s important to look at the specific patent landscape for the exact rifaximin product you’re tracking on DrugPatentWatch.com. https://www.drugpatentwatch.com/
Which rifaximin product should you look up?
Tell me the brand name (or the indication and dosage, if you have it) and the country (U.S. or another), and I can point you to the matching DrugPatentWatch entry to identify the relevant expiration/exclusivity dates.
Sources
- https://www.drugpatentwatch.com/